We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 69

Supreme Court of Canada Bulletin - December 14, 2017
  • Gowling WLG
  • USA, Canada
  • December 14 2017

On appeal from a judgment of the British Columbia Court of Appeal (2016 BCCA 200), setting aside in part a decision of Brown J. (2015 BCSC 1170)...


Coming soon to Canadian medical device manufacturers? “Failure to train" cases south of the border
  • Gowling WLG
  • USA, Canada
  • December 21 2016

Medical device manufacturers (“MDMs”) often have to defend against novel theories of liability put forward by plaintiff counsel. The most recent


Guide to Doing Business in Canada
  • Gowling WLG
  • USA, United Kingdom, OECD, Canada, Global
  • October 14 2016

Unlike the United States, Canada was not created by a unilateral declaration of independence from the colonial occupation of England. There was no


Coming soon to Canadian medical device manufacturers? "Failure to train" cases south of the border
  • Gowling WLG
  • USA, Canada
  • October 21 2014

Medical device manufacturers (“MDMs”) often have to defend against novel theories of liability put forward by plaintiff counsel. The most recent


Northern exposure?
  • Gowling WLG
  • USA, Canada
  • April 4 2013

Davit Akman and John Norman suggest that a recently commenced investigation into alleged "product switching" and statements by the Interim


Life sciences & law current issues 201213
  • Gowling WLG
  • USA, Canada, European Union
  • June 18 2012

Each stage of the life cycle of a company or a product presents challenges that demand the expertise and resources of a strong legal partner.


The U.S. Prometheus decision and claims to methods of optimizing dosing regimens: Mayo Collaborative Services v. Prometheus Laboratories, Inc., U.S., No. 10-1150
  • Gowling WLG
  • USA, Canada
  • April 11 2012

In a decision last month, the U.S. Supreme Court in a 9-0 ruling has held that the method claims of two patents directed to optimizing the dose of a specific drug for treating an autoimmune disease are not patentable because they merely recite laws of nature.


Isabel Raasch
  • Gowling WLG